We’re at the point in the cycle where dollars donated to Psymposia will get better ROI than dollars to MAPS. Psychedelics aren’t going away at this point. Powerful tools must be handled with care, lest they cause more harm than good.
At this point it seems like Psymposia’s MO is that MAPS is the scandal, and is generating bad science. Not sure I 100% agree but I think it’s a point worth considering.
I don't know about that.
- Not even a single psychedelic has been taken off Schedlue 1 (the most prohibited category) in the US.
- Only MDMA therapy has reached Phase 3 trials and is ready for mainstream adoption.
- Despite all the research done on psychedelics, our understanding of how and why they work, and of their potential is still in its infancy.
- It's still difficult to do large double-blind, placebo controlled studies with psychedelics due to funding shortages.
- Most people still don't know much about psychedelics and have never tried them.
Psymposia does good work in exposing scandals, but doesn't do anything to address any of the above issues.
MAPS still has a long, long way to go and is every bit as deserving of funding as it ever was.